EV MDA5 agonism has an intriguing innate footprint, characterized by polar TBK1-IFN regulatory factor 3 (IRF3) signaling, which fuels sustained type-I IFN release to provide context for antitumor CD8+ T-cell priming after in situ cancer vaccination. This evidence concerns the gene IRF3 and cancer.